Phenytoin vs Zonisamide (Zonegran)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channels · full Epilepsy pipeline
Phenytoin
Marketed by Viatris and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Zonisamide (Zonegran)
Marketed by Advanz Pharma and partners
NCT00056576 · Phase 3 · completed
Although 165 participants were reportedly randomized and treatment was double-blinded, the study is listed as a single-group design with no placebo or active comparator. No primary endpoint or results are posted, so whether the primary outcome was met or missed cannot be assessed.
Reported efficacy
Percentage of Participants Remaining in the Study at Each Visit (At 3, 6, 9, 12, 15, 18, 21, 24, and 27 months): Long-term extension; the registered primary was retention in the study at each visit, with no formal test. Retention at 12 months: zonisamide 58.4% (n=137) vs carbamazepine 61.4% (n=158) (CT.gov posted results). (not_applicable)
Result source: NCT00848549
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Phenytoin | Zonisamide (Zonegran) |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT00210782 | -48.4% vs -26.6%−21.8 vs placeboNCT003277171 other result
|
| 50% responder rate | —Not posted · NCT00210782 | 48.6% vs 34.9%+13.7 vs placeboNCT003277171 other result
|
| Seizure freedom | —Not posted · NCT00210782 | 1.8% vs 2.8%−1 vs placeboNCT00327717 |
Seizure frequency, % change
- Phenytoin
- —Not posted · NCT00210782
- Zonisamide (Zonegran)
- -48.4% vs -26.6%−21.8 vs placeboNCT00327717
1 other result
- -32.7% vs -35.6% NCT00292461
50% responder rate
- Phenytoin
- —Not posted · NCT00210782
- Zonisamide (Zonegran)
- 48.6% vs 34.9%+13.7 vs placeboNCT00327717
1 other result
- 45.8% vs 45.8% NCT00292461
Seizure freedom
- Phenytoin
- —Not posted · NCT00210782
- Zonisamide (Zonegran)
- 1.8% vs 2.8%−1 vs placeboNCT00327717
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Phenytoin: 3 of 4 rows · Zonisamide (Zonegran): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Phenytoin | Zonisamide (Zonegran) |
|---|---|---|
| Dropout rate | 38.2%a NCT00510783 · Phase 4 · registry result, not featured evidence | 42.9%Zonisamidea NCT00848549 · Phase 3 · monotherapy show 12 more results—Zonisamide (Base Study 310, NCT004 NCT00848549 · Phase 3 · monotherapy —Zonisamide (Extension Study 314, N NCT00848549 · Phase 3 · monotherapy 27.3% NCT01140867 · Phase 4 · registry result, not featured evidence 31.7%high dose NCT01127165 · Phase 4 · registry result, not featured evidence 24.6%low dose NCT01127165 · Phase 4 · registry result, not featured evidence — NCT00855738 · Phase 4 · registry result, not featured evidence 29.2%Zonisamide (Zonisamide During Core NCT01136954 · Phase 3 · registry result, not featured evidence 33.3%Zonisamide(Placebo During Core Stu NCT01136954 · Phase 3 · registry result, not featured evidence 13.1% NCT00566254 · Phase 3 · registry result, not featured evidence 42.9% NCT00477295 · Phase 3 · registry result, not featured evidence 29.4% NCT00292461 · Phase 3 · registry result, not featured evidence 7.5%100 mg NCT00327717 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00510783 · Phase 4 · registry result, not featured evidence | 11%Zonisamidea NCT00848549 · Phase 3 · monotherapy show 12 more results—Zonisamide (Base Study 310, NCT004 NCT00848549 · Phase 3 · monotherapy —Zonisamide (Extension Study 314, N NCT00848549 · Phase 3 · monotherapy 18.2% NCT01140867 · Phase 4 · registry result, not featured evidence 3.3%high dose NCT01127165 · Phase 4 · registry result, not featured evidence 3.1%low dose NCT01127165 · Phase 4 · registry result, not featured evidence — NCT00855738 · Phase 4 · registry result, not featured evidence 2.8%Zonisamide (Zonisamide During Core NCT01136954 · Phase 3 · registry result, not featured evidence 4.2%Zonisamide(Placebo During Core Stu NCT01136954 · Phase 3 · registry result, not featured evidence 0.9% NCT00566254 · Phase 3 · registry result, not featured evidence 11% NCT00477295 · Phase 3 · registry result, not featured evidence 11.8% NCT00292461 · Phase 3 · registry result, not featured evidence 5%100 mg NCT00327717 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 0%a NCT00510783 · Phase 4 · registry result, not featured evidence | —Zonisamidea NCT00848549 · Phase 3 · monotherapy show 12 more results5.3%Zonisamide (Base Study 310, NCT004 NCT00848549 · Phase 3 · monotherapy 5.1%Zonisamide (Extension Study 314, N NCT00848549 · Phase 3 · monotherapy 1.7% NCT01140867 · Phase 4 · registry result, not featured evidence 1.7%high dose NCT01127165 · Phase 4 · registry result, not featured evidence 3.1%low dose NCT01127165 · Phase 4 · registry result, not featured evidence 0% NCT00855738 · Phase 4 · registry result, not featured evidence 9.7%Zonisamide (Zonisamide During Core NCT01136954 · Phase 3 · registry result, not featured evidence 4.2%Zonisamide(Placebo During Core Stu NCT01136954 · Phase 3 · registry result, not featured evidence 3.7% NCT00566254 · Phase 3 · registry result, not featured evidence 5.3% NCT00477295 · Phase 3 · registry result, not featured evidence 0% NCT00292461 · Phase 3 · registry result, not featured evidence 0%100 mg NCT00327717 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | a dizziness 9.2% fatigue 9.2% burning at the iv site 6.6% NCT00510783 · Phase 4 · registry result, not featured evidence | show 11 more resultsdizziness 28.1% somnolence 24% anorexia 18.2% NCT01140867 · Phase 4 · registry result, not featured evidence high dose dizziness 5% micturition disorder 5% somnolence 5% NCT01127165 · Phase 4 · registry result, not featured evidence low dose anorexia 4.6% fatigue 3.1% somnolence 3.1% NCT01127165 · Phase 4 · registry result, not featured evidence somnolence 7.5% weight increased 5% dizziness 2.5% NCT00855738 · Phase 4 · registry result, not featured evidence nasopharyngitis 12.5% headache 9.7% weight decreased 8.3% NCT01136954 · Phase 3 · registry result, not featured evidence nasopharyngitis 8.3% weight decreased 8.3% decreased appetite 6.9% NCT01136954 · Phase 3 · registry result, not featured evidence decreased appetite 6.5% (placebo 4%) headache 6.5% (placebo 7%) nasopharyngitis 5.6% (placebo 9%) NCT00566254 · Phase 3 · registry result, not featured evidence headache 10.3% decreased appetite 7.8% weight decreased 6.8% NCT00477295 · Phase 3 · registry result, not featured evidence hepatic enzyme abnormal 8.8% blood alkaline phosphatase increased 5.9% dizziness 5.9% NCT00292461 · Phase 3 · registry result, not featured evidence 100 mg anorexia 18.3% (placebo 5.1%) somnolence 12.5% (placebo 14.4%) headache 10.8% (placebo 5.1%) NCT00327717 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Phenytoin
Zonisamide (Zonegran)
show 4 more results
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 15 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Phenytoin's landscape · Zonisamide (Zonegran)'s landscape